An effective biotech pitch deck, or corporate slide deck, needs to sell both your science and your company to potential investors. To help you craft a clear, persuasive deck that delivers results, we’re sharing a series of proven Theoria Creative strategies and templates as a guide. This article is part
An effective biotech pitch deck, or corporate slide deck, needs to sell both your science and your company to potential investors. To help you craft a clear, persuasive deck that delivers results, we’re sharing a series of proven Theoria Creative strategies and templates as a guide. This article is part
An effective biotech pitch deck, or corporate slide deck, needs to sell both your science and your company to potential investors. To help you craft a clear, persuasive deck that delivers results, we’re sharing a series of proven Theoria Creative strategies and templates as a guide. This article is part
An effective biotech pitch deck, or corporate slide deck, needs to sell both your science and your company to potential investors. To help you craft a clear, persuasive deck that delivers results, we’re sharing a series of proven Theoria Creative strategies and templates as a guide. This article is part
An effective biotech pitch deck, or corporate slide deck, needs to sell both your science and your company to potential investors. To help you craft a clear, persuasive deck that delivers results, we’re sharing a series of proven Theoria Creative strategies and templates as a guide. This article is part
Growing biotech companies require significant investment to stay afloat. Often, confidence in a company’s potential hinges on the clarity and persuasiveness of their biotech pitch deck. At Theoria Creative, we carefully consider each slide when we develop investor presentation decks for clients. Every word, graphic, and high-level message is strategically chosen to
Reflecting on 2024, the biotech industry considerably advanced in gene editing, oncology, and AI-driven drug discovery and saw increased M&A activity. We also witnessed a notable shift toward immunology, with innovations from oncology beginning to influence treatments for immunology and autoimmune diseases. As the year draws to a close, we’re
Through our work with a diverse range of clients and investors, we encounter numerous stories that are truly worth sharing. Caleb B. Bell III, PhD, is one such investor and collaborator with a noteworthy story. With a doctorate in biophysical chemistry from Stanford University, Caleb has spent decades as both
We share useful tips and company news in a monthly newsletter.
